Tiplaxtinin(PAI-039)
(Synonyms: ALPHA-氧代-1-(苯基甲基)-5-[4-(三氟甲氧基)苯基]-1H-吲哚-3-乙酸,PAI-039; Tiplasinin) 目录号 : GC12387
Tiplaxtinin(PAI-039)是一种口服生物利用的尿激酶型纤溶酶原激活物抑制剂-1(PAI-1)拮抗剂,IC50值为2.7μM。
Cas No.:393105-53-8
Sample solution is provided at 25 µL, 10mM.
Tiplaxtinin(PAI-039) is an orally bioavailable antagonist of plasminogen activator inhibitor-1 (PAI-1) with IC50 value of 2.7μM. Tiplaxtinin is commonly employed in studies of antithrombosis, diabetic wound healing, and skeletal-muscle regeneration[1][2].
In vitro, the human cervical carcinoma (CC) cell lines HeLa and SiHa were treated with Tiplaxtinin at concentrations of 20µM, 40µM, 60µM, 80µM, and 100µM for 24h to72h. Tiplaxtinin showed a strong inhibitory effect on both SiHa and HeLa cells, significantly reducing their viability, colony formation, and migratory capacity[3]. Immortalized human keratinocytes HaCaT cells were incubated with 10µM Tiplaxtinin for 24h or 72h. Tiplaxtinin reduces PAI-1-stimulated keratinocyte migration in vitro while having no effect on epithelial proliferation, cell cycle progression, or apoptosis[4].
In vivo, male C57BL/6-Ins2 Akita/J mice were treated via oral gavage with vehicle (2% Tween-80 and 0.5% methylcellulose in sterile H2O) or vehicle plus Tiplaxtinin (2mg/kg) after becoming spontaneously diabetic at about 4 weeks of age due to a heterozygous mutation in the Ins-2 gene. Tiplaxtinin administration reversed the diabetic defect by promoting macrophage and satellite cell infiltration into necrotic areas of the tibialis anterior and gastrocnemius[5]. Tiplaxtinin (5mg/day) were orally administrated into mice model of chronic allergic asthma from 1 day before ovalbumin or PBS challenge until Day 36. Tiplaxtinin significantly reduced the bronchoalveolar lavage fluid levels of active PAI-1, the degree of inflammation, airway remodeling, and airway hyperresponsiveness in a murine model of chronic asthma[6]. Tiplaxtinin was administered by oral gavage to athymic mice bearing human bladder cancer cell line T24 xenografts and human cervical cancer HeLa cell xenografts. The subcutaneous tumor growth of both T24 and HeLa cell xenografts treated with tiplaxtinin was markedly reduced compared with untreated controls[7].
References:
[1] Hennan J K, Morgan G A, Swillo R E, et al. Effect of Tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis. J Thromb Haemost. 2008 Sep;6(9):1558-64.
[2] Rebalka I R, Raleigh M J, D'Souza D M, et al. Inhibition of PAI-1 Via PAI-039 Improves Dermal Wound Closure in Diabetes. Diabetes. 2015 Jul;64(7):2593-602.
[3] Wehbe S, Gallwas J, Gründker C. Inhibition of Plasminogen Activator Inhibitor-1 (PAI-1) by Tiplaxtinin Reduces Aggressiveness of Cervical Carcinoma Cells. Anticancer Res. 2025 May;45(5):1793-1805.
[4] Simone T M, Longmate W M, Law B K, Higgins P J. Targeted Inhibition of PAI-1 Activity Impairs Epithelial Migration and Wound Closure Following Cutaneous Injury. Adv Wound Care (New Rochelle). 2015 Jun 1;4(6):321-328.
[5] Krause M P, Sajee D A, D'Souza D M, et al. Impaired macrophage and satellite cell infiltration occurs in a muscle-specific fashion following injury in diabetic skeletal muscle. PLoS One. 2013 Aug 12;8(8):e70971.
[6] Lee S H, Eren M, Vaughan D E, et al. A plasminogen activator inhibitor-1 inhibitor reduces airway remodeling in a murine model of chronic asthma. Am J Respir Cell Mol Biol. 2012 Jun;46(6):842-6.
[7] Giacoia E G, Miyake M, Goodison S, Rosser C J. Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. Mol Cancer Ther. 2013, Dec;12(12):2697-708.
Tiplaxtinin(PAI-039)是一种口服生物利用的尿激酶型纤溶酶原激活物抑制剂-1(PAI-1)拮抗剂,IC50值为2.7μM。Tiplaxtinin常被用于抗血栓、糖尿病伤口愈合和骨骼肌再生等研究[1][2]。
体外实验中,人宫颈癌细胞系HeLa和SiHa分别以20µM、40µM、60µM、80µM和100µM浓度的Tiplaxtinin处理24h至72h。Tiplaxtinin对SiHa和HeLa细胞表现出强烈抑制作用,显著降低其活力、集落形成能力和迁移能力[3]。永生化人角质形成细胞HaCaT以10µM Tiplaxtinin孵育24h或72h,Tiplaxtinin在体外抑制了PAI-1刺激的角质形成细胞迁移,而对上皮增殖、细胞周期进展或凋亡无影响[4]。
体内实验中,雄性C57BL/6-Ins2 Akita/J小鼠因Ins-2基因杂合突变于约4周龄自发形成糖尿病,随后经口灌胃给予空白对照溶媒(2%Tween-80和0.5%甲基纤维素无菌H2O)或溶媒加Tiplaxtinin(2mg/kg)。Tiplaxtinin给药通过促进巨噬细胞和卫星细胞浸润至胫骨前肌和腓肠肌坏死区域,逆转了糖尿病缺陷[5]。在慢性过敏性哮喘小鼠模型中,从卵清蛋白或PBS刺激前1天至第36天,每日口服给予Tiplaxtinin(5mg/day)。Tiplaxtinin显著降低支气管肺泡灌洗液中活性PAI-1水平、炎症程度、气道重塑及气道高反应性[6]。将Tiplaxtinin经口灌胃给予携带人膀胱癌细胞系T24异种移植物和人宫颈癌HeLa细胞异种移植物的裸鼠,T24和HeLa细胞异种移植物的皮下肿瘤生长较未处理对照显著减退[7]。
Cell experiment [1]: | |
Cell lines | Immortalized human keratinocytes (HaCaT cells) |
Preparation Method | Confluent HaCaT cells were switched to serum free media before scratch wounding and concomitant treatment with 10µM Tiplaxtinin for 24h or 72h. |
Reaction Conditions | 10µM; 24h or 72h |
Applications | Tiplaxtinin reduces PAI-1-stimulated keratinocyte migration in vitro while having no effect on epithelial proliferation, cell cycle progression, or apoptosis. |
Animal experiment [2]: | |
Animal models | C57BL/6 mice |
Preparation Method | C57BL/6 mice were divided into four groups; phosphate-buffered saline (PBS) only (group 1); PBS 1 tiplaxtinin (group 2); OVA only (group 3); and OVA 1 tiplaxtinin (group 4). Mice were sensitized via three intraperitoneal injections (on Days 0, 3, and 6) of 50mg/0.1ml chicken OVA. After sensitization, the mice were exposed to aerosolized PBS or OVA (10mg/15ml OVA in PBS) for 20min/day on 3day/week for 4 weeks, beginning from the 11th day of the study. Tiplaxtinin was mixed with regular chow and administrated orally to groups 2 and 4 at a dose of 5mg/day, from 1 day before challenge until Day 36. |
Dosage form | 5mg/day; orally administration; from 1 day before challenge until Day 36 |
Applications | Tiplaxtinin significantly reduced the bronchoalveolar lavage fluid levels of active PAI-1, the degree of inflammation, airway remodeling, and airway hyperresponsiveness in a murine model of chronic asthma |
References: |
Cas No. | 393105-53-8 | SDF | |
别名 | ALPHA-氧代-1-(苯基甲基)-5-[4-(三氟甲氧基)苯基]-1H-吲哚-3-乙酸,PAI-039; Tiplasinin | ||
化学名 | 2-(1-benzyl-5-(4-(trifluoromethoxy)phenyl)-1H-indol-3-yl)-2-oxoacetic acid | ||
Canonical SMILES | FC(F)(OC1=CC=C(C2=CC(C(C(C(O)=O)=O)=CN3CC4=CC=CC=C4)=C3C=C2)C=C1)F | ||
分子式 | C24H16F3NO4 | 分子量 | 439.38 |
溶解度 | ≥ 17.6mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.2759 mL | 11.3797 mL | 22.7593 mL |
5 mM | 0.4552 mL | 2.2759 mL | 4.5519 mL |
10 mM | 0.2276 mL | 1.138 mL | 2.2759 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet